ArticleExperimental and therapeutic medicine2015
Significance of human epidermal growth factor receptor 2 expression in colorectal cancer.
Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Trial
- Assessment of HER2/Neu Expression in Colorectal Carcinomas and Its Correlation With Tumor Stage and Histopathology.Cureus · 2025Article
- Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review).Oncology letters · 2023Review
- Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies.Cancers · 2022Review
- Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population.Frontiers in oncology · 2022Article
- Article
- HER2 Overexpression and Mismatch Repair Deficiency are Correlated with Malignancy in Colorectal Cancer.Cancer management and research · 2021Article
- lncRNA PDIA3P regulates cell proliferation and invasion in non-small cell lung cancer.Experimental and therapeutic medicine · 2019Article
- Article
- Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status.World journal of clinical cases · 2018Review
- Correlation of HER2 and FOXM1 in human colorectal carcinoma and its clinical significance.International journal of clinical and experimental pathology · 2017Article
- Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer.Experimental and therapeutic medicine · 2016Article
- HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Oncotarget · 2016Review
- HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.World journal of gastroenterology · 2016Review
- Anti-inflammatory and Antitumor Activity of a Triple Therapy for a Colitis-Related Colorectal Cancer.Journal of Cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to evaluate the protein expression level of human epidermal growth factor receptor 2 (HER-2) using immunohistochemistry (IHC), and assess the association with clinicopathological parameters and the prognosis of patients with colorectal cancer (CRC). In addition, the current study observed the consistency between the levels of HER-2 protein expression determined by IHC and HER-2 gene amplification determined by fluorescence
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.